Allosteric Cooperativity Mechanism Investigation of Orthosteric and Allosteric Ligands in Modulating AR Activity: A Molecular Dynamics Study.

Abstract

The androgen receptor (AR) represents a pivotal therapeutic target for prostate cancer. However, existing orthosteric ligand-binding pocket (LBP) antagonists [e.g., enzalutamide (ENZ)] encounter significant obstacles due to resistance-conferring mutations in the LBP. Allosteric antagonists targeting the BF3 site exhibit great potential in overcoming such resistance but have low inhibitory efficacy. In our study, we employed an integrated computational modeling strategy, including Gaussian-accelerated molecular dynamics (GaMD), MM/GBSA free-energy calculations, and elastic network model (ENM)-based signaling communication pathway analyses. This approach is used to probe the cooperativity of allosteric BF3 antagonists [e.g., VPC-13808 (VPC)] with diverse orthosteric LBP ligands [e.g., ENZ and testosterone (TES)] in suppressing AR activity. Herein, four types of AR systems were examined: AR bound to LBP agonist (AR·TES), LBP antagonists (e.g., AR·ENZ), and combinations of LBP agonist/antagonist with BF3 antagonist (e.g., AR·TES·VPC and AR·ENZ·VPC). Results indicate that BF3 antagonists can synergize with the LBP antagonist to amplify conformational flexibility in H12 and induce anticorrelated dynamics of H12 with H3 and H4. This induces the downward movement of H12 and its displacement away from H3/H4, triggering the wide opening of the AF2 binding cleft and substantially reducing the coactivator recruitment. Furthermore, the BF3 antagonist can interact with specific residues (e.g., F673, F826, L830, and Y834) and cooperate with the LBP agonist or antagonist to allosterically perturb the AF2 conformation. Multiple short- and/or long-range BF3→AF2 and LBP→AF2 signaling transition pathways are involved, such as F673→Y834→L722→L812→L744→V746→L873→ENZ→L880/V889/V891. These mechanistic insights establish the foundation for developing novel AR BF3 antagonist and LBP-BF3 combination therapies, suggesting a promising avenue for enhancing the efficacy and overcoming the resistance in castration-resistant prostate cancer treatment.